New hope for rare nerve disease? early trial tests KINE-101
NCT ID NCT07343310
First seen Jan 19, 2026 · Last updated May 21, 2026 · Updated 17 times
Summary
This early study tested a new drug called KINE-101 in 9 adults with a rare nerve disease (CIDP) that did not improve with standard steroid treatment. The main goal was to check if a single dose of the drug is safe and tolerable. Researchers monitored participants for 28 days after the dose to track side effects and look for early signs of benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIDP - CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kangbuk Samsung Hospital
Seoul, Seoul, 03181, South Korea
-
Samsung Medical Center
Seoul, Seoul, 06351, South Korea
Conditions
Explore the condition pages connected to this study.